Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Blood biomarkers have proven useful in Alzheimer's disease (AD) research. However, little is known about their biological variation (BV), which improves the interpretation of individual‐level data. METHODS: We measured plasma amyloid beta (Aβ42, Aβ40), phosphorylated tau (p‐tau181, p‐tau217, p‐tau231), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) in plasma samples collected weekly over 10 weeks from 20 participants aged 40 to 60 years from the European Biological Variation Study. We estimated within‐ (CV I ) and between‐subject (CV G ) BV, analytical variation, and reference change values (RCV). RESULTS: Biomarkers presented considerable variability in CV I and CV G . Aβ42/Aβ40 had the lowest CV I (≈ 3%) and p‐tau181 the highest (≈ 16%), while others ranged from 6% to 10%. Most RCVs ranged from 20% to 30% (decrease) and 25% to 40% (increase). DISCUSSION: BV estimates for AD plasma biomarkers can potentially refine their clinical and research interpretation. RCVs might be useful for detecting significant changes between serial measurements when monitoring early disease progression or interventions. Highlights: Plasma amyloid beta (Aβ42/Aβ40) presents the lowest between‐ and within‐subject biological variation, but also changes the least in Alzheimer's disease (AD) patients versus controls. Plasma phosphorylated tau variants significantly vary in their within‐subject biological variation, but their substantial fold‐changes in AD likely limits the impact of their variability. Plasma neurofilament light chain and glial fibrillary acidic protein demonstrate high between‐subject variation, the impact of which will depend on clinical context. Reference change values can potentially be useful in monitoring early disease progression and the safety/efficacy of interventions on an individual level. Serial sampling revealed that unexpectedly high values in heathy individuals can be observed, which urges caution when interpreting AD plasma biomarkers based on a single test result.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 2×
“43,71 Such high-value outliers are not uncommon in A β -negative groups when examining data points from recent cross-sectional studies, 4–6 and we recommend caution for researchers and clinicians when interpreting AD blood biomarker results from a single sample.”
BackgroundMethodSelf-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 1×
“12,67,68 16 Our BV findings further support that plasma A β 42/A β 40 will likely face long-term difficulties if introduced in clinical practice.”
BackgroundMattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationBenedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Self-citationHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Self-citationPlasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598
Self-citationSandberg, S., Fraser, C. G., Horvath, A. R., Jansen, R., Jones, G., Oosterhuis, W., Petersen, P. H., Schimmel, H., Sikaris, K., & Panteghini, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0067 · Cited by 563
Self-citationA multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545 · cited 2×
“1,2 22–26 Furthermore,allofthese biomarker candidates have beenevaluated as potential surrogate end-points in disease-modifying clinical trials in AD, with a recent example beingreductionsinplasmap-tau217asearlyasafter12weeksoftreat-ment with a promising anti-A β monoclonal antibody, donanemab.”
BackgroundInfluentialSelf-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationHead-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3180 · Cited by 494 · cited 1×
“13 Considering previous BV studies showing different assay versions for thesameanalytepresentindistinguishableCV I s,itisexpectedthatthe CV I for plasma A β 42/A β 40 would be similar across assays.”
MethodSelf-citationPerformance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465
Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436
Self-citationMilà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353
Self-citationPontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3392 · Cited by 261
Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00471-5 · Cited by 248
Self-citationAarsand, A. K., Røraas, T., Fernandez-Calle, P., Ricos, C., Díaz-Garzón, J., Jonker, N., Perich, C., González-Lao, E., Carobene, A., Minchinela, J., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.281808 · Cited by 233 · cited 4×
“30,31 Such studies require the serial, tightly controlled collection of samples from healthy individuals with a regular sampling rate, and that analytes should be quantified, at least, in duplicate.”
BackgroundMethodInfluentialSelf-citationAshton, N. J., Puig‐Pijoan, A., Milà‐Alomà, M., Fernández‐Lebrero, A., García‐Escobar, G., González‐Ortiz, F., Kac, P. R., Brum, W. S., Benedet, A. L., Lantero‐Rodriguez, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12841 · Cited by 230
Self-citationAnalytical performance characteristics should be judged against objective quality specifications
Fraser, C. G., & Petersen, P. H. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.3.321 · Cited by 194
A checklist for critical appraisal of studies of biological variation
Bartlett, W. A., Braga, F., Carobene, A., Coşkun, A., Prusa, R., Fernandez-Calle, P., Røraas, T., Jonker, N., Sandberg, S., & Variati, O. B. O. T. B. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1127 · Cited by 151 · cited 1×
“0) Smokers, n (%) 1 (10) 0 1 (5) Physical exercise, n (%) 8 (80) 5 (50) 13 (65) No physical exercise 2 (20) 5 (50) 7 (35) < 3h per week 1 (10) 1 (10) 2 (10) ≥ 3 7 (70) 4 (40) 11 (55) Study center, n (%) Italy (Milan) 2 (20) 2 (20) 4 (20) Italy (Padua) 3 (30) 0 3 (15) Netherlands 3 (30) 2 (20) 5 (25) Norway 2 (20) 3 (3…”
Self-citationAl Shweiki, M. R., Steinacker, P., Oeckl, P., Hengerer, B., Danek, A., Fassbender, K., Diehl-Schmid, J., Jahn, H., Anderl-Straub, S., Ludolph, A. C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.019 · Cited by 131
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00405-1 · Cited by 122
Self-citationCoşkun, A., Sandberg, S., Unsal, I., Cavusoglu, C., Serteser, M., Kilercik, M., & Aarsand, A. K. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa233 · Cited by 112 · cited 5×
“33,36 European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group on Biological Variation.”
BackgroundInfluentialSelf-citationCarobene, A., Strollo, M., Jonker, N., Barla, G., Bartlett, W. A., Sandberg, S., Sylte, M. S., Røraas, T., Sølvik, U. Ø., Fernandez-Calle, P., et al. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0035 · Cited by 110
Self-citationAarsand, A. K., Díaz-Garzón, J., Fernandez-Calle, P., Guerra, E., Locatelli, M., Bartlett, W. A., Sandberg, S., Røraas, T., Ceriotti, F., Sølvik, U. Ø., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.288415 · Cited by 105
Self-citationPlasma neurofilament light predicts mortality in patients with stroke
Gendron, T. F., Badi, M. K., Heckman, M. G., Jansen-West, K. R., Vilanilam, G. K., Johnson, P. W., Burch, A. R., Walton, R. L., Ross, O. A., Brott, T. G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1913 · Cited by 92 · cited 2×
“24,26,64 While it is not yet clear what GFAP in the blood reflects (showing unexpected differences against CSF GFAP), 65 it has been associated with A β pathology, showing promising diagnostic performance, 18,20 even though increased GFAP levels have been reported in A β -negative neurodegenerative…”
BackgroundInfluentialClark, C., Lewczuk, P., Kornhuber, J., Richiardi, J., Maréchal, B., Karikari, T. K., Blennow, K., Zetterberg, H., & Popp, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00805-8 · Cited by 88 · cited 1×
“43,71 Such high-value outliers are not uncommon in A β -negative groups when examining data points from recent cross-sectional studies, 4–6 and we recommend caution for researchers and clinicians when interpreting AD blood biomarker results from a single sample.”
BackgroundSelf-citationVillain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
The European Biological Variation Study (EuBIVAS): a summary report
Carobene, A., Aarsand, A. K., Bartlett, W. A., Coskun, A., Diaz-Garzon, J., Fernandez-Calle, P., Guerra, E., Jonker, N., Locatelli, M., Plebani, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0370 · Cited by 84 · cited 3×
“37,38”
MethodSelf-citationCarobene, A., Marino, I., Coşkun, A., Serteser, M., Unsal, I., Guerra, E., Bartlett, W. A., Sandberg, S., Aarsand, A. K., Sylte, M. S., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.275115 · Cited by 77 · cited 1×
“47,52 Further, the desirable bias is also considerably low for plasma A β 42/A β 40 (B APS = 3.7%; Table 4), and it is unlikely that batch-to-batch variations could be kept low enough to meet this APS.”
BackgroundInfluentialSelf-citationBiological Variation Estimates Obtained from 91 Healthy Study Participants for 9 Enzymes in Serum
Carobene, A., Røraas, T., Sølvik, U. Ø., Sylte, M. S., Sandberg, S., Guerra, E., Marino, I., Jonker, N., Barla, G., Bartlett, W. A., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.269811 · Cited by 63
Self-citationBenussi, A., Cantoni, V., Rivolta, J., Archetti, S., Micheli, A., Ashton, N., Zetterberg, H., Blennow, K., & Borroni, B. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01094-5 · Cited by 53
Self-citationCarobene, A., Guerra, E., Locatelli, M., Cucchiara, V., Briganti, A., Aarsand, A. K., Coşkun, A., Díaz-Garzón, J., Fernandez-Calle, P., Røraas, T., et al. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.07.043 · Cited by 47
Self-citationBottani, M., Aarsand, A. K., Banfi, G., Locatelli, M., Coşkun, A., Díaz-Garzón, J., Fernandez-Calle, P., Sandberg, S., Ceriotti, F., & Carobene, A. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1885 · Cited by 46
Self-citationHaeckel, R., Wosniok, W., Kratochvila, J., & Carobene, A. (2012) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2011-0862 · Cited by 33 · cited 1×
“0) Smokers, n (%) 1 (10) 0 1 (5) Physical exercise, n (%) 8 (80) 5 (50) 13 (65) No physical exercise 2 (20) 5 (50) 7 (35) < 3h per week 1 (10) 1 (10) 2 (10) ≥ 3 7 (70) 4 (40) 11 (55) Study center, n (%) Italy (Milan) 2 (20) 2 (20) 4 (20) Italy (Padua) 3 (30) 0 3 (15) Netherlands 3 (30) 2 (20) 5 (25) Norway 2 (20) 3 (3…”
Self-citationA blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
Monane, M., Johnson, K. G., Snider, B. J., Turner, R. S., Drake, J. D., Maraganore, D. M., Bicksel, J. L., Jacobs, D. H., Ortega, J. L., Henderson, J., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51863 · Cited by 32 · cited 1×
“12,67,68 16 Our BV findings further support that plasma A β 42/A β 40 will likely face long-term difficulties if introduced in clinical practice.”
BackgroundCarobene, A., Banfi, G., Locatelli, M., & Vidali, M. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.09.018 · Cited by 24 · cited 4×
“33,36 We also calculated the number of samples needed to be collected to estimate an individual’s homeostatic point (NHSP) with a “D” absolute percentage proximity to the individual’s true value with the equation n Note : The table summarizes key demographic information for the included…”
BackgroundInfluentialSelf-citationCarobene, A., Guerra, E., Locatelli, M., Ceriotti, F., Sandberg, S., Fernandez-Calle, P., Coşkun, A., & Aarsand, A. K. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.292169 · Cited by 22
Self-citation
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Dubois, B., Villain, N., Schneider, L., Fox, N., Campbell, N., Galasko, D., Kivipelto, M., Jessen, F., Hanseeuw, B., Boada, M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3770 · Cited by 426
Self-citationHu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Beament, M., Wiltshire, K., Belder, C. R. S., Abel, E., Hart, M., Heslegrave, A. J., Lunn, M. P., Rosa-Grilo, M., Swann, O., Schott, J. M., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02180-8
Self-citation
Metadata
- Authors
- Brum, W. S., Ashton, N. J., Simrén, J., di Molfetta, G., Karikari, T. K., Benedet, A. L., Zimmer, E. R., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Jeromin, A., Aarsand, A. K., Bartlett, W. A., Calle, P. F., Coşkun, A., Díaz–Garzón, J., Jonker, N., Zetterberg, H., Sandberg, S., Carobene, A., & Blennow, K.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2023-11-20
- Volume
- 20
- Issue
- 2
- Pages
- 1284-1297
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4388851280
- Cited by
- 76
- References
- 42
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.